News & Events

9 July 2024

Different clinical profiles of alcohol-related hepatitis versus infection-induced ACLF

In this collaborative presentation of A-TANGO's first major early-career scientists' (ECS) poster, Annarein Kerbert, a medical doctor (MD, PhD) at Leiden University Medical Center (LUMC, Netherlands), and Julian Pohl, a medical doctor (MD) at the Charité in Berlin (Germany), reveal the different clinical profiles of patients with alcohol-related hepatitis and acute-on-chronic liver failure (ACLF) versus infection-induced ACLF. The poster was presented at the annual congress of the European Association for the Study of the Liver (EASL Congress) in Milan, Italy, on Thursday, 6 June 2024 (poster number: THU-057-YI). View the full video on YouTube.

5 July 2024

The clinical burden of liver cirrhosis in the past years, including the pandemic

On the final day of this year's EASL Congress in Milan Italy (Saturday, 8 June 2024), we met with A-TANGO early-career scientist (ECS) Julian Pohl, a medical doctor at the Charité - Universitätsmedizin Berlin, at his poster (Poster-ID: SAT-452) to hear about how the clinical burden of cirrhosis and acute-on-chronic liver failure (ACLF) has evolved and changed over the past years. The COVID-19 pandemic had particular effects on the hospitalisation rate of cirrhotic patients and the severity and mortality of the disease. Watch the full video on YouTube for more insights.

20 June 2024

New Masterclass video on health economics in liver disease

In this Masterclass, Prof. Dr. Isabelle Durand-Zaleski – A-TANGO member at partner AP-HP in Paris (France) – provides an introduction on why and how to perform economic evaluations in healthcare, specifically for liver diseases like advanced cirrhosis. The Masterclass was recorded as part of the early-career scientists (ECS) agenda during the (remote) 3rd A-TANGO General Assembly (GA) Meeting on 26th September 2023. View on YouTube!


More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more


  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more


Prof. Dr. Rajiv Jalan (EF CLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona


Dr. med. Cornelius Engelmann (MD, PhD) (Charité)
Augustenburger Platz 1
13353 Berlin


concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck